165 related articles for article (PubMed ID: 34600176)
1. The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib.
Zhang X; Zhang JG; Mu W; Zhou HM; Liu GL; Li Q
Phytomedicine; 2021 Nov; 92():153740. PubMed ID: 34600176
[TBL] [Abstract][Full Text] [Related]
2. COE inhibits vasculogenic mimicry in hepatocellular carcinoma via suppressing Notch1 signaling.
Jue C; Min Z; Zhisheng Z; Lin C; Yayun Q; Xuanyi W; Feng J; Haibo W; Youyang S; Tadashi H; Shintaro I; Shiyu G; Yanqing L
J Ethnopharmacol; 2017 Aug; 208():165-173. PubMed ID: 28694103
[TBL] [Abstract][Full Text] [Related]
3. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
4. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
Zheng N; Zhang S; Wu W; Zhang N; Wang J
Pharmacol Res; 2021 Apr; 166():105507. PubMed ID: 33610718
[TBL] [Abstract][Full Text] [Related]
5. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
Ma D; Wang J; Liu L; Chen M; Wang Z
BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
[TBL] [Abstract][Full Text] [Related]
6. Incarvine C suppresses proliferation and vasculogenic mimicry of hepatocellular carcinoma cells via targeting ROCK inhibition.
Zhang JG; Zhang DD; Wu X; Wang YZ; Gu SY; Zhu GH; Li XY; Li Q; Liu GL
BMC Cancer; 2015 Oct; 15():814. PubMed ID: 26510899
[TBL] [Abstract][Full Text] [Related]
7. Notch1 promotes vasculogenic mimicry in hepatocellular carcinoma by inducing EMT signaling.
Jue C; Lin C; Zhisheng Z; Yayun Q; Feng J; Min Z; Haibo W; Youyang S; Hisamitsu T; Shintaro I; Shiyu G; Yanqing L
Oncotarget; 2017 Jan; 8(2):2501-2513. PubMed ID: 27705934
[TBL] [Abstract][Full Text] [Related]
8. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
[No Abstract] [Full Text] [Related]
9. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
10. Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma.
Meng J; Sun B; Zhao X; Zhang D; Zhao X; Gu Q; Dong X; Zhao N; Liu P; Liu Y
Mol Cancer Ther; 2014 Dec; 13(12):3107-22. PubMed ID: 25277383
[TBL] [Abstract][Full Text] [Related]
11. RhoC/ROCK2 promotes vasculogenic mimicry formation primarily through ERK/MMPs in hepatocellular carcinoma.
Zhang JG; Zhang DD; Liu Y; Hu JN; Zhang X; Li L; Mu W; Zhu GH; Li Q; Liu GL
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1113-1125. PubMed ID: 30779947
[TBL] [Abstract][Full Text] [Related]
12. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
13. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
14. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
15. Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT.
Xiao T; Bao J; Tian J; Lin R; Zhang Z; Zhu Y; He Y; Gao D; Sun R; Zhang F; Cheng Y; Shaletanati J; Zhou H; Xie C; Yang C
Phytomedicine; 2023 Apr; 112():154687. PubMed ID: 36804756
[TBL] [Abstract][Full Text] [Related]
16. Notch4 inhibition suppresses invasion and vasculogenic mimicry formation of hepatocellular carcinoma cells.
Cheng R; Cai XR; Ke K; Chen YL
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):719-725. PubMed ID: 29058285
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic induction of vasculogenic mimicry in hepatocellular carcinoma: role of HIF-1 α, RhoA/ROCK and Rac1/PAK signaling.
Zhang JG; Zhou HM; Zhang X; Mu W; Hu JN; Liu GL; Li Q
BMC Cancer; 2020 Jan; 20(1):32. PubMed ID: 31931758
[TBL] [Abstract][Full Text] [Related]
18. [MIG7 Regulates the Vasculogenic Mimicry Formation in Hepatocellular Carcinoma then Effects the Metastasis Potential of HCC].
Qu B; Yu F; Sheng GN; Chen GN; Lü Q; Gu YJ; Guo L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 May; 48(3):373-377. PubMed ID: 28616909
[TBL] [Abstract][Full Text] [Related]
19. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
[TBL] [Abstract][Full Text] [Related]
20. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
Hu C; Li W; Tian F; Jiang K; Liu X; Cen J; He Q; Qiu Z; Kienast Y; Wang Z; Zhang H; Ji Y; Hu J; Hui L
J Hepatol; 2018 Mar; 68(3):465-475. PubMed ID: 29113912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
